Learn more about HIV/AIDS and share to help raise awareness.
Early HIV detection, viral load monitoring, and testing for the drug-resistance of particular strains of HIV may improve patient outcomes and reduce disease transmission. Clinical laboratory tests remain critically important at every stage of the HIV-care continuum, as they provide clinicians with answers that allow them to manage patients more effectively.
Siemens Healthineers offers HIV testing solutions for early identification of HIV-positive individuals that help clinicians care for and treat patients and provide knowledge needed for prevention. Siemens Healthineers has solutions for:
HIV Ag/Ab Combo (CHIV) Assay
The CDC and European guidelines recommend the use of a fourth-generation HIV screening test for maximum sensitivity and specificity.
The CHIV assay available on the Atellica® IM Analyzer and ADVIA Centaur Immunoassay Systems is a fourth-generation HIV assay offering both excellent sensitivity and specificity. It was designed with patented AE technology to meet current laboratory requirements and future needs for accurate HIV diagnostic testing. The assay offers:
- Earlier detection capability using a fully automated qualitative combo HIV assay that simultaneously detects the presence of HIV-1 p24 antigen and antibodies to HIV-1 (including group O) and HIV-2 in serum and plasma
- Elimination of sample carryover and associated potential for false-positive results with use of disposable sample tips and a one-way workflow
HIV Risk Factors
Recognize the risk factors to help prevent the spread of HIV.
According to the World Health Organization, primary risk factors for HIV include unprotected vaginal or anal sex; sharing contaminated needles, syringes, and other injecting equipment; unsafe blood transfusions and medical procedures; accidental needle-stick injuries; and other sexually transmitted infections, such as syphilis, herpes, chlamydia, gonorrhea, and bacterial vaginosis.1
HIV Prevention, Testing, and Therapy
Limiting exposure and curbing behavior associated with the risk factors can reduce the probability of HIV infection.
Identifying infections using blood tests such as the Atellica® IM and ADVIA Centaur® HIV Combo Immunoassay are important to manage patients and communities more effectively.
Despite the many challenges of the HIV epidemic, some progress has been made. Globally there were 21.7 million people receiving ART in 2017, an increase of 2.3 million since 2016 and up from 8 million in 2010.2
However, there is renewed concern that the annual number of new infections among adults has remained static in recent years. In 2017, there were roughly 1.8 million new HIV infections – the same as in 2016. Global new HIV infections have declined by just 18% in the past seven years, from 2.2 million in 2010 to 1.8 million in 2017. In 2017 an estimated 36.9 million people were living with HIV and roughly 25% of these same people do not know that they have the virus.3
One simple blood test could save lives.